Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Presurgical endocrine and COX-2 modulation in estrogen receptor-positive breast cancer
ISRCTN86894592Phase 2Completed
- Sponsor
- European Institute of Oncology
- Start
- Feb 2004
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of raloxifene, tamoxifen, exemestane and celecoxib in breast cancer (6 arms), sponsored by European Institute of Oncology. Primary endpoint: Change in Ki-67 expression. Started Feb 2004; status: completed.
02
Drugs
raloxifenetamoxifenexemestanecelecoxib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN86894592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN86894592.